Dexmedetomidine and Propofol for Pediatric MRI Sedation

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 4, 2018

Primary Completion Date

August 21, 2018

Study Completion Date

October 21, 2018

Conditions
HeadacheTumorSeizure DisorderNeurofibromatosesHydrocephalusAbdominal NeoplasmSpine Deformity
Interventions
DRUG

propofol

propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists

DRUG

Dexmedetomidine

single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg

DRUG

Glycopyrrolate

4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group

DRUG

Lidocaine 1% Injectable Solution

1 mg/kg intravenous administration prior to propofol administration

DRUG

Nitrous Oxide

Inhalation of nitrous oxide may be used for IV placement

DRUG

Sevoflurane

Inhalation of sevoflurane may be used for IV placement

Trial Locations (1)

53226

Children's Hospital of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT03513757 - Dexmedetomidine and Propofol for Pediatric MRI Sedation | Biotech Hunter | Biotech Hunter